N/A
N=371
Dynamic Coronary Roadmap for Contrast Reduction
Coronary Artery Disease
Bottom Line
View on ClinicalTrials.gov: NCT04085614 ↗Enrolled (actual)
371
Serious AEs
5.9%
Results posted
Jan 2024
Primary outcome: Primary: Total Percutaneous Coronary Intervention (PCI) Iodinated Contrast Volume — 64.6; 90.8 ml
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap (Device); Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Philips Clinical & Medical Affairs Global
- Primary completion
- Feb 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Percutaneous Coronary Intervention (PCI) Iodinated Contrast Volume |
64.6; 90.8 | — |
| SECONDARY Number of Angiograms |
8.7; 11.7 | — |
Summary
The Dynamic Coronary Roadmap is a commercially available product developed by Philips Medical Systems, a Philips Healthcare company. Dynamic Coronary Roadmap is a software medical device intended to provide a real-time and dynamic angiographic roadmap of coronary arteries. The angiographic roadmap is automatically generated from previously acquired coronary angiograms during the same procedure. Dynamic Coronary Roadmap overlays the angiographic roadmap on live 2D fluoroscopic images, thereby assisting the physician in navigating devices, e.g. (guide) wires, catheters, through the coronary arteries.
This is a multi-center, prospective, unblinded, stratified 1:1 randomized controlled trial to assess whether using Dynamic Coronary Roadmap reduces the total iodinated contrast volume related to Percutaneous Coronary Intervention (PCI) compared to the control group without Dynamic Coronary Roadmap.
Eligibility Criteria
Inclusion Criteria
- Subject is undergoing Percutaneous Coronary Intervention (PCI) with a degree of complexity that anticipates the need for more than 25ml of iodinated contrast volume
- Subject has signed informed consent
- Subject is 18 years of age or older, or of legal age to give informed consent per state or national law
Exclusion Criteria
- Subject undergoing emergency Percutaneous Coronary Intervention (PCI)
- Subject with ST-segment Elevation Myocardial Infarction (STEMI)
- Subject with Chronic Total Occlusion (CTO)
- Subject undergoing PCI for isolated ostial disease of Left Main Coronary Artery (LMCA) or Right Coronary Artery (RCA)
- Subject undergoing Percutaneous Coronary Intervention (PCI) with Optical Coherence Tomography (OCT) support
- Subject undergoing Percutaneous Coronary Intervention (PCI) with rotational or orbital atherectomy
- Subject with Chronic Kidney Disease (CKD) stage V (estimated Glomerular Filtration Rate (eGFR) < 15 ml/min/1.73 m^2)
- Subject with contrast allergy that cannot be adequately pre-medicated
- Subject participates in a potentially confounding drug or device trial during the course of the study.
- Subject is under 18 years of age, or pregnant woman, or breast feeding woman, or meets an exclusion criteria according to national law
Data sourced from ClinicalTrials.gov (NCT04085614). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.